Forest, Pierre Fabre drug 'significantly' reduced depression symptoms

Drug makers conduct phase-3 study of levomilnacipran

NEW YORK — A drug under development by Forest Labs and Pierre Fabre "significantly" reduced symptoms of major depressive disorder, the companies said Wednesday.

New York-based Forest and Paris-based Pierre Fabre announced results of a phase-3 trial of levomilnacipran, saying the drug showed reductions in symptoms as early as one week after treatment was started. The companies expect results of another phase-3 trial of the drug this spring.

The study included 442 men and women ages 18 to 80 years, who first received placebo for a week and were then randomly placed into a treatment group or a placebo group for eight weeks.


Interested in this topic? Sign up for our weekly DSN Collaborative Care e-newsletter.

Recommended stories

Login or Register to post a comment.